CA Healthcare’s Board Recommends Stockholders
Vote “FOR” the Business Combination and “FOR” all of the related
proposals
All stockholders of CA Healthcare as of
September 1st, 2021 are encouraged to vote their shares in advance
of the Special Meeting
Stockholders who need assistance voting their
shares should contact CA Healthcare’s proxy solicitor, Morrow
Sodali, at 203-658-9400 or via email at
cahc@info.morrowsodali.com
CA Healthcare Acquisition Corp. (NASDAQ: CAHC) (“CA
Healthcare”), a publicly traded special purpose acquisition
company, and LumiraDx Limited (“LumiraDx”), a next-generation point
of care diagnostics testing company, announced that the U.S.
Securities and Exchange Commission (the “SEC”) has declared
effective LumiraDx’s registration statement on Form F-4 (File No.
333-257745) relating to the previously announced merger of CA
Healthcare and LumiraDx. On September 3, 2021, CA Healthcare filed
a definitive proxy relating to the proposed business
combination.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20210907005874/en/
CA Healthcare will mail stockholders as of September 1, 2021
(the “Record Date”) the definitive proxy statement/prospectus
relating to the Special Meeting of CA Healthcare Stockholders (the
“Special Meeting”), to be held on September 28th, 2021 at 9:00 a.m.
ET. Stockholders will have until September 27th, 2021 at 11:59 p.m.
ET to vote. Voting is easy and can be done in one of two ways:
online or by mail. All CA Healthcare stockholders as of the Record
Date are encouraged to vote for the transaction.
“We are excited about the transaction with LumiraDx and look
forward to entering the final phase of our merger process,” said
Larry Neiterman, Chief Executive Officer of CA Healthcare.
Details of the Special Meeting
The Special Meeting to approve the pending business combination
between CA Healthcare and LumiraDx, among other items, is scheduled
for September 28, 2021, at 9:00 a.m. ET. The Special Meeting will
be completely virtual and conducted via live webcast. Holders of CA
Healthcare common stock as of the close of business on the Record
Date may vote at or before the virtual Special Meeting and are
encouraged to vote before 11:59 p.m. ET on September 27, 2021.
CA Healthcare has filed with the SEC a definitive proxy
statement/prospectus relating to the Special Meeting and will mail
the proxy statement/prospectus to stockholders who owned CA
Healthcare common stock as of the Record Date.
CA Healthcare stockholders can exercise their votes online or by
mail. CA Healthcare stockholders who need assistance voting or have
questions regarding the Special Meeting may contact CA Healthcare’s
proxy solicitor, Morrow Sodali, toll-free at (203) 658-9400 or
email Morrow Sodali at cahc@info.morrowsodali.com.
If certain of the proposals at the Special Meeting are approved,
the parties anticipate the business combination will close shortly
thereafter, subject to the satisfaction or waiver (as applicable)
of all other closing conditions.
About LumiraDx
LumiraDx is a next-generation point of care diagnostics company
that is transforming community-based healthcare. Founded in 2014,
the company manufactures and commercializes an innovative
diagnostic Platform that supports a broad menu of tests with lab
comparable performance at the point of care. LumiraDx’s diagnostic
testing solutions are being deployed by governments and leading
healthcare institutions across laboratories, urgent care, physician
offices, pharmacy, schools, and workplaces to screen, diagnose and
monitor wellness as well as disease. The company has on the market
and in development 30+ tests covering infectious diseases,
cardiovascular disease, diabetes and coagulation disorders, all on
the LumiraDx Platform. In addition, the company has a comprehensive
portfolio of fast, accurate and cost-efficient COVID-19 testing
solutions from the lab to point of need.
Based in the UK with more than 1500 employees worldwide,
LumiraDx is supported by institutional and strategic investors
including the Bill & Melinda Gates Foundation, Morningside
Ventures, U.S. Boston Capital Corporation, and Petrichor Healthcare
Capital Management.
More information may be found at LumiraDx.com.
About CA Healthcare Acquisition Corp.
CA Healthcare Acquisition Corp. is a special purpose acquisition
company formed for the purpose of effecting a merger, capital stock
exchange, asset acquisition, stock purchase, reorganization or
similar business combination with one or more businesses. For more
information, visit www.cahcspac.com/.
Forward-Looking Statements
Certain statements in this press release may be considered
“forward-looking statements” within the meaning of the “safe
harbor” provisions of the United States Private Securities
Litigation Reform Act of 1995. Forward-looking statements generally
relate to future events or CA Healthcare’s or LumiraDx’s future
financial or operating performance. For example, projections of
future revenue and other metrics are forward-looking statements. In
some cases, you can identify forward-looking statements by
terminology such as “may,” “should,” “expect,” “intend,” “will,”
“estimate,” “anticipate,” “believe,” “predict” or the negatives of
these terms or variations of them or similar terminology. Such
forward-looking statements are subject to risks, uncertainties, and
other factors which could cause actual results to differ materially
from those expressed or implied by such forward-looking statements.
These forward-looking statements are based upon estimates and
assumptions that, while considered reasonable by CA Healthcare and
its management, and LumiraDx and its management, as the case may
be, are inherently uncertain. Factors that may cause actual results
to differ materially from current expectations include, but are not
limited to: 1) the occurrence of any event, change or other
circumstances that could give rise to the termination of the
definitive merger agreement with respect to the business
combination; 2) the outcome of any legal proceedings that may be
instituted against CA Healthcare, LumiraDx or others following the
announcement of the business combination and any definitive
agreements with respect thereto; 3) the inability to complete the
business combination due to the failure to obtain approval of the
securityholders of CA Healthcare or LumiraDx or to satisfy other
conditions to closing; 4) changes to the proposed structure of the
business combination that may be required or appropriate as a
result of applicable laws or regulations; 5) the ability to meet
the Nasdaq’s listing standards following the consummation of the
business combination; 6) the risk that the business combination
disrupts current plans and operations of LumiraDx as a result of
the announcement and consummation of the business combination; 7)
the ability to recognize the anticipated benefits of the business
combination, which may be affected by, among other things,
competition, the ability of LumiraDx to grow and manage growth
profitably, maintain relationships with customers, manufacturers
and suppliers and retain its management and key employees; 8) costs
related to the business combination; 9) changes in applicable laws
or regulations; 10) the possibility that LumiraDx may be adversely
affected by other economic, business and/or competitive factors;
11) LumiraDx’s estimates of its financial performance; and 12)
other risks and uncertainties set forth in the section entitled
“Risk Factors” and “Cautionary Note Regarding Forward-Looking
Statements” in CA Healthcare’s Registration Statement on form S-1
filed with the Securities and Exchange Commission (“SEC”) on
January 8, 2021 and the registration statement on Form F-4 and
proxy statement/prospectus discussed below. Nothing in this press
release should be regarded as a representation by any person that
the forward-looking statements set forth herein will be achieved or
that any of the contemplated results of such forward looking
statements will be achieved. You should not place undue reliance on
forward-looking statements, which speak only as of the date they
are made. Neither CA Healthcare nor LumiraDx undertakes any duty to
update these forward-looking statements, except as otherwise
required by law.
Additional Information About the Proposed Business
Combination and Where to Find It
In connection with the proposed business combination, CA
Healthcare has filed with the SEC a definitive proxy
statement/prospectus and has mailed the definitive proxy
statement/prospectus relating to the proposed business combination
to its shareholders. This press release does not contain all the
information that should be considered concerning the proposed
business combination and is not intended to form the basis of any
investment decision or any other decision in respect of the
business combination. CA Healthcare’s shareholders and other
interested persons are advised to read the definitive proxy
statement/prospectus and other documents filed in connection with
the proposed business combination, as these materials will contain
important information about LumiraDx, CA Healthcare and the
proposed business combination. The definitive proxy
statement/prospectus and other relevant materials for the proposed
business combination have been mailed to shareholders of CA
Healthcare as of the Record Date for voting on the proposed
business combination. Such shareholders will also be able to obtain
copies of the definitive proxy statement/prospectus and other
documents filed with the SEC, without charge at the SEC’s website
at www.sec.gov, or by directing a request to CA Healthcare
Acquisition Corp., 99 Summer Street, Suite 200 Boston, MA
02110.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities, or a solicitation
of any vote or approval, nor shall there be any sale of securities
in any jurisdiction in which such offer, solicitation or sale would
be unlawful prior to the registration or qualification under the
securities laws of any such jurisdiction. No offering of securities
shall be made except by means of a prospectus meeting the
requirements of Section 10 of the U.S. Securities Act of 1933, as
amended.
Participants in the Solicitation
CA Healthcare and its directors and executive officers may be
deemed participants in the solicitation of proxies from CA
Healthcare’s shareholders with respect to the proposed business
combination. A list of the names of those directors and executive
officers and a description of their interests in CA Healthcare is
contained in the definitive proxy statement/prospectus. Additional
information regarding the interests of such participants is
contained in the proxy statement/prospectus for the proposed
business combination.
LumiraDx and its directors and executive officers may also be
deemed to be participants in the solicitation of proxies from the
shareholders of CA Healthcare in connection with the proposed
business combination. A list of the names of such directors and
executive officers and information regarding their interests in the
proposed business combination is contained in the definitive proxy
statement/prospectus. Additional information regarding the
interests of such participants is contained in the proxy
statement/prospectus for the proposed business combination.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210907005874/en/
Media: Travis Kruse, Ph.D. tkruse@apcoworldwide.com +1
949 648 7286
Investor: Aman Patel, CFA IR@lumiradx.com +1 443 450
4191
CA Healthcare Acquisition (NASDAQ:CAHC)
Historical Stock Chart
From Aug 2024 to Sep 2024
CA Healthcare Acquisition (NASDAQ:CAHC)
Historical Stock Chart
From Sep 2023 to Sep 2024